Response Genetics' Q1 Revenues Increase 59 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Increased use of its ResponseDx genetic tests drove up Response Genetics' first-quarter revenues 59 percent year over year, the company said today.

The Los Angeles-based cancer molecular diagnostic test developer said that for the three months ended March 31, revenues increased to $5.9 million from $3.7 million, in part due to an 82 percent increase in revenues associated with its ResponseDx tests for colon, lung, and gastric cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.